A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute; London Health Sciences Centre
• Collaborator: The Ottawa Hospital
• Treatments: Albumin-Bound Paclitaxel; Cyclophosphamide; Docetaxel; Paclitaxel; Trastuzumab

Criteria

Inclusion Criteria:

• Patients with HER-2 positive early stage breast cancer for whom TC-H or weekly P-H is being considered.

• Able to provide verbal consent.

• Willing to complete study related-questionnaires

Exclusion Criteria:

• Unable to give informed consent or complete questionnaires